CervoMed Inc
CRVO9.370USD
+0.540+6.12%
交易中 （美東）報價延遲15分鐘
81.54M總市值
虧損本益比TTM
關於 CervoMed Inc 公司
CervoMed Inc. 是一家臨牀階段的生物技術公司，專注於開發與年齡相關的神經系統疾病的治療方法。該公司專注於開發其主要候選藥物 neflamapimod，這是一種口服小分子腦滲透劑，可抑制神經退行性疾病患者腦內神經元（神經細胞）中的 p38a。該公司的 neflamapimod 正處於臨牀開發階段，作爲一種用於治療神經退行性疾病（如路易體癡呆和早期阿爾茨海默病）的疾病改良療法。此外，臨牀前數據支持 neflamapimod 在卒中後康復中的潛在作用。neflamapimod 有可能治療和改善突觸功能障礙，這是路易體癡呆 (DLB) 和某些其他神經系統疾病的潛在疾病過程的可逆性方面。該公司正在進行的 RewinD-LB 試驗正在對其進行評估，這是一項針對 DLB 患者的 2b 期研究。
公司簡介
公司代碼CRVO
公司名稱CervoMed Inc
上市日期Nov 09, 2016
CEOMr. John J. Alam, M.D.
員工數量15
證券類型Ordinary Share
年結日Nov 09
公司地址20 Park Plaza, Suite 424
城市BOSTON
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編02116
電話16177444400
網址https://cervomed.com/
公司代碼CRVO
上市日期Nov 09, 2016
CEOMr. John J. Alam, M.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Joshua S. Boger, Ph.D.
Dr. Joshua S. Boger, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.06M
--
Mr. John J. Alam, M.D.
Mr. John J. Alam, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
730.79K
+0.17%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Independent Director
Independent Director
16.44K
--
Ms. Kelly Blackburn
Ms. Kelly Blackburn
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
13.67K
--
Ms. Jane H. Hollingsworth, M.D.
Ms. Jane H. Hollingsworth, M.D.
Independent Director
Independent Director
899.00
--
Mr. William R. Elder
Mr. William R. Elder
Chief Financial Officer, General Counsel, Corporate Secretary
Chief Financial Officer, General Counsel, Corporate Secretary
--
--
Dr. Marwan Noel Sabbagh, M.D.
Dr. Marwan Noel Sabbagh, M.D.
Independent Director
Independent Director
--
--
Dr. Claudia Ordonez, M.D.
Dr. Claudia Ordonez, M.D.
Senior Vice President - Medical Science
Senior Vice President - Medical Science
--
--
Dr. Marco Verwijs, Ph.D.
Dr. Marco Verwijs, Ph.D.
Executive Vice President - Technical Operations
Executive Vice President - Technical Operations
--
--
Dr. Robert J. Cobuzzi, Jr.
Dr. Robert J. Cobuzzi, Jr.
Director
Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Joshua S. Boger, Ph.D.
Dr. Joshua S. Boger, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.06M
--
Mr. John J. Alam, M.D.
Mr. John J. Alam, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
730.79K
+0.17%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Independent Director
Independent Director
16.44K
--
Ms. Kelly Blackburn
Ms. Kelly Blackburn
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
13.67K
--
Ms. Jane H. Hollingsworth, M.D.
Ms. Jane H. Hollingsworth, M.D.
Independent Director
Independent Director
899.00
--
Mr. William R. Elder
Mr. William R. Elder
Chief Financial Officer, General Counsel, Corporate Secretary
Chief Financial Officer, General Counsel, Corporate Secretary
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Boger (Joshua S)
12.15%
AWM Investment Company, Inc.
9.92%
Gregoire (Sylvie L.)
8.40%
Alam (John J)
8.40%
The Vanguard Group, Inc.
4.35%
Other
56.79%
持股股東
持股股東
佔比
Boger (Joshua S)
12.15%
AWM Investment Company, Inc.
9.92%
Gregoire (Sylvie L.)
8.40%
Alam (John J)
8.40%
The Vanguard Group, Inc.
4.35%
Other
56.79%
股東類型
持股股東
佔比
Individual Investor
33.43%
Investment Advisor/Hedge Fund
14.17%
Investment Advisor
10.36%
Research Firm
1.60%
Hedge Fund
0.09%
Bank and Trust
0.06%
Pension Fund
0.02%
Other
40.27%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
117
5.20M
59.72%
-1.49M
2025Q1
117
5.20M
61.51%
-1.51M
2024Q4
109
4.40M
53.34%
-2.51M
2024Q3
92
6.43M
77.88%
-414.79K
2024Q2
78
6.37M
77.13%
+108.27K
2024Q1
52
5.40M
90.18%
+2.52M
2023Q4
54
3.10M
54.81%
+657.18K
2023Q3
54
3.32M
58.71%
+3.16M
2023Q2
46
125.98K
9.26%
-42.41K
2023Q1
54
143.15K
10.53%
-17.76K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Boger (Joshua S)
1.06M
12.15%
--
--
Apr 24, 2025
AWM Investment Company, Inc.
863.20K
9.92%
+863.20K
--
Mar 31, 2025
Gregoire (Sylvie L.)
730.79K
8.4%
-1.25K
-0.17%
Apr 24, 2025
Alam (John J)
730.79K
8.4%
+1.25K
+0.17%
Apr 24, 2025
The Vanguard Group, Inc.
378.66K
4.35%
-4.83K
-1.26%
Mar 31, 2025
Zavrl (Frank E.)
353.01K
4.06%
--
--
Apr 24, 2025
BlackRock Institutional Trust Company, N.A.
321.48K
3.69%
+24.03K
+8.08%
Mar 31, 2025
Morgan Stanley & Co. LLC
130.60K
1.5%
+87.90K
+205.86%
Mar 31, 2025
Geode Capital Management, L.L.C.
116.48K
1.34%
+1.65K
+1.43%
Mar 31, 2025
State Street Global Advisors (US)
112.06K
1.29%
-4.20K
-3.61%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Health Innovation Active ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
iShares Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
佔比0.01%
iShares Russell 2000 Growth ETF
佔比0%
Global X Russell 2000 ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
ProShares UltraPro Russell2000
佔比0%
iShares Health Innovation Active ETF
佔比0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
佔比0%
iShares Russell 2000 ETF
佔比0%
ProShares Hedge Replication ETF
佔比0%
Avantis US Small Cap Equity ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Aug 16, 2023
Merger
1.5<1
Aug 16, 2023
Merger
1.5<1
Aug 16, 2023
Merger
1.5<1
Aug 16, 2023
Merger
1.5<1
Apr 18, 2022
Merger
50<1
Apr 18, 2022
Merger
50<1
公告日期
類型
比率
Aug 16, 2023
Merger
1.5<1
Aug 16, 2023
Merger
1.5<1
Aug 16, 2023
Merger
1.5<1
Aug 16, 2023
Merger
1.5<1
Apr 18, 2022
Merger
50<1
Apr 18, 2022
Merger
50<1
Apr 18, 2022
Merger
50<1
Apr 18, 2022
Merger
50<1
